Dosing time based on molecular mechanism of biological clock of hepatic drug metabolic enzyme

Yakugaku Zasshi

Volumn 129, Issue 11, 2009, Pages 1357-1365

  Matsunaga, Naoya ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Acetaminophen; Circadian rhythm; Clock genes; Cytochrome P450 2E1; Hepatic nuclear factor

Indexed keywords

CYTOCHROME P450 2E1; DRUG METABOLIZING ENZYME; GLUCURONIC ACID; GLUTATHIONE; HEPATIC NUCLEAR FACTOR 1ALPHA; MESSENGER RNA; N ACETYL 1,4 BENZOQUINONE IMINE; PARACETAMOL; SULFURIC ACID; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; BIOLOGICAL RHYTHM; CHRONOPHARMACOLOGY; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ELIMINATION; DRUG FATALITY; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; EXPERIMENTAL MOUSE; GENETIC TRANSCRIPTION; GLUTATHIONE METABOLISM; LIVER; LIVER TOXICITY; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; REVIEW;

ACETAMINOPHEN; ANALGESICS; ANIMALS; BENZOQUINONES; BIOLOGICAL CLOCKS; CIRCADIAN RHYTHM; CYTOCHROME P-450 CYP2E1; DRUG CHRONOTHERAPY; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; IMINES; INDIVIDUALIZED MEDICINE; LIVER; MICE; SUPRACHIASMATIC NUCLEUS;

EID: 70450169816     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.129.1357     Document Type: Review

References (40)

1. Ogawa N., Ohdo S., Nihon Rinsho, 51, 2778-2787 (1993).
2. Ohdo S., Nakano S., Ogawa N., J. Clin. Pharmacol., 32, 822-826 (1992).
3. Dunlap J. C., Cell, 96, 271-290 (1999).
4. Reppert S. M., Weaver D. R., Nature, 418, 935-941 (2002).
5. Gekakis N., Staknis D., Nguyen H. B., Davis F. C., Wilsbacher L. D., King D. P., Takahashi J. S., Weitz C. J., Science, 280, 1564-1569 (1998).
6. Kume K., Zylka M. J., Sriram S., Shearman L. P., Weaver D. R., Jin X., Maywood E. S., Hastings M. H., Reppert S. M., Cell, 98, 193-205 (1999).
7. Shigeyoshi Y., Taguchi K., Yamanoto S., Takekida S., Yan L., Tei H., Moriya T., Shibata S., Loros J. J., Dunlap J. C., Okamura H., Cell, 91, 1043-1053 (1997).
8. Ohdo S., Gekkan Yakuji, 44, 752-764 (2002).
9. Smolensky M. H., Labrecque G., Pharmaceutical news, 4, 10-16 (1997).
10. D'Alonzo G. E., Smolensky M. H., Feldman S., Gianotti L. A., Emerson M. B., Staudinger H., Steinijans V. W., Am. Rev. Respir. Dis, 142, 84-90 (1990).
11. Jamali F., Thomson A. B., Kirdeikis P., Tavernini M., Zuk L., Marriage B., Simpson I., Mahachai V., J. Clin. Pharmacol., 35, 1071-1075 (1995).
12. Ohdo S., Koyanagi S., Suyama H., Higuchi S., Aramaki H., Nature Medicine, 7, 356-360 (2001).
13. Koyanagi S., Kuramoto Y., Nakagawa H., Aramaki H., Ohdo S., Soeda S., Shimeno H., Cancer Res., 63, 7277-7283 (2003).
14. Nakagawa H., Koyanagi S., Takiguchi T., Kuramoto Y., Soeda S., Shimeno H., Higuchi S., Ohdo S., Cancer Res., 64, 8328-8333 (2004).
15. Viyoch J., Matsunaga N., Yoshida M., To H., Higuchi S., Ohdo S., J. Biol. Chem., 280, 6309-6315 (2005).
16. Terazono H., Hamdan A., Matsunaga N., Hayasaka N., Kaji H., Egawa T., Makino K., Shigeyoshi Y., Koyanagi S., Ohdo S., Biochem. Pharmacol, 75, 1616-1622 (2008).
17. Murakami Y., Higashi Y., Matsunaga N., Koyanagi S., Ohdo S., Gastroenterology, 135, 1636-1644 (2008).
18. Ohdo S., Drug Metab. Pharmacokinet., 22, 3-14 (2007).
19. Ueda H. R., Chen W., Adachi A., Wakamatsu H., Hayashi S., Takasugi T., Nagano M., Nakahama K., Suzuki Y., Sugano S., Iino M., Shigeyoshi Y., Hashimoto S., Nature, 418, 534-539 (2002).
20. Takiguchi T., Tomita M., Matsunaga N., Nakagawa H., Koyanagi S., Ohdo S., Pharmacogenet. Genomics, 17, 1047-1056 (2007).
21. Matsunaga N., Nakamura N., Yoneda N., Qin T., Terazono H., To H., Higuchi S., Ohdo S., J. Pharmacol. Exp. Ther., 311, 594-600 (2004).
22. Matsunaga N., Ikeda M., Takiguchi T., Koyanagi S., Ohdo S., Hepatology, 48, 240-251 (2008).
23. Nelson S. D., Drug Metab. Rev., 27, 147-177 (1995).
24. Dahlin D. C., Miwa G. T., Lu A. Y., Nelson S. D., Proc. Natl. Acad. Sci. USA, 81, 1327-1331 (1984).
25. Gonzalez F. J., Toxicol. Lett., 28, 161-166 (1998).
26. Mitchell J. R., Corcoran G. B., Smith C. V., Hughes H., Lauterburg P. H., Nelson E. B., "Drug Reactions and the Liver," eds. by Davis M., Tredger J. M., Williams R., Pitman Medical, London, 1981, pp. 130-143.
27. Thomas S. H., Pharm. Ther., 60, 91-120 (1993)
28. Schnell R. C., Bozigian H. P., Davies M. H., Merrick B. A., Johnson K. L., Toxicol. Appl. Pharmacol., 71, 353-361 (1983).
29. Gekakis N., Staknis D., Nguyen H. B., Davis F. C., Wilsbacher L. D., King D. P., Takahashi J. S., Weitz C. J., Science, 280, 1564-1569 (1998).
30. Tanaka E., Terada M., Misawa S., J. Clin. Pharm. Ther., 25, 165-175 (2000).
31. Gonzalez F. J., Drug. Metab. Dispos., 35, 1-8 (2007).
32. Ulusoy G., Adali O., Tumer T. B., Sahin G., Gozdasoglu S., Arinc E., Oncology, 72, 125-131 (2007).
33. Cereghini S., FASEB J., 10, 267-282 (1996).
34. Ueno T., Gonzalez F. J., Mol. Cell. Biol., 10, 4495-4505 (1990).
35. Cheung C., Akiyama T. E., Kudo G., Gonzalez F. J., Biochem. Pharmacol., 66, 2011-2020 (2003).
36. Glass C. K., RosenfeldM. G., Genes Dev., 15, 121-141 (2000).
37. Orphanides G, Reinberg D., Cell, 108, 439-451 (2002).
38. Etchegaray J. P., Lee C., Wade P. A., Reppert S. M., , Nature, 421, 177-182 (2003).
39. Naruse Y., Oh-hashi K., Iijima N., Naruse M., Yoshioka H., Tanaka M., Mol. Cell. Biol., 24, 6278-6287 (2004).
40. Soutoglou E., Papafotiou G., Katrakili N., Talianidis I., J. Biol. Chem., 275, 12515-12520 (2000).